Healthcare giant Abbott has launched its next-generation continuous glucose monitoring (CGM) device, FreeStyle Libre 2 Plus, in India. The device provides real-time glucose readings every minute, with optional alarms for high or low sugar levels.
Unlike previous versions, the new sensor transmits data directly to a smartphone without manual scans, can be worn for up to 15 days, and integrates with Abbott’s digital health platforms LibreView and LibreLinkUp, enabling remote monitoring by caregivers and doctors.
Abbott did not disclose the device’s price in India. Globally, its FreeStyle Libre portfolio is used by over 7 million people across 60 countries.
“With 101 million people living with diabetes, India has the world’s second-largest diabetic population. FreeStyle Libre 2 Plus empowers people to manage their condition better with accuracy and freedom from routine fingersticks,” said Dr. Kenneth Lee, Regional Medical Affairs Director, Abbott.
